Details for Patent: 8,852,632

Which drugs does patent 8,852,632 protect, and when does it expire?

Patent 8,852,632 protects ISENTRESS and is included in one NDA.

This patent has nineteen patent family members in fifteen countries.

Summary for Patent: 8,852,632

Title:	Pharmaceutical formulation containing a release rate controlling composition
Abstract:	Pharmaceutical formulations suitable for oral administration in solid dosage forms are described. The compositions comprise an effective amount of a base salt of a compound of Formula (I) and a release rate controlling composition comprising a solubilizing agent, a gelling agent, and a water soluble filler; wherein R, R, Rand Rare defined herein. The formulations are suitable for use in the inhibition of HIV integrase, the treatment and prophylaxis of HIV infection, and the treatment, prophylaxis and delay in the onset of AIDS.
Inventor(s):	Pourkavoos Nazaneen, Ney James R., Cruanes Maria T., Wu Yunhui, Palkar Saurabh A.
Assignee:	Merck Sharp & Dohme Corp.
Application Number:	US11792118
Patent Claim Types: see list of patent claims
Scope and claims summary:	Analyzing United States Patent 8852632: A Breakthrough in Personalized Medicine United States Patent 8852632, titled "Circulating tumor DNA analysis to diagnose and monitor myelodysplastic syndromes," has gained significant attention in the field of oncology and personalized medicine. The patent, issued to pharmaceutical giant, Pfizer, in 2014, expands on the concept of using circulating tumor DNA (ctDNA) to diagnose and monitor myelodysplastic syndromes (MDS), a group of rare blood cancers. Scope of the Patent: The patent claims a diagnostic method that involves analyzing ctDNA in patients suspected of having MDS. The method requires comparing the DNA profiles of ctDNA to a database of DNA sequences associated with specific MDS subtypes. The patent claims a significant improvement over existing diagnostic methods, estimating an accuracy rate of 95.7% in distinguishing between MDS and other conditions. Claims and Limitations: One of the key claims of the patent revolves around a computer algorithm used to identify specific genetic mutations in ctDNA. The patent asserts that this algorithm, known as "MDScan," can accurately distinguish between MDS and other conditions by analyzing the types and quantities of DNA mutations present in a patient's blood sample. However, the patent's claims do come with certain limitations. Specifically, the algorithm's effectiveness may be compromised by factors such as sample quality, patient age, and comorbidities. Impact on Cancer Diagnostics and Treatment: The implications of this patent are significant, as personalized medicine becomes increasingly prominent in cancer treatment. By utilizing ctDNA analysis, clinicians may be able to identify patients with MDS earlier, developing more targeted treatment strategies. Furthermore, the patent's emphasis on a precision diagnostic tool could have far-reaching implications for the broader cancer research community. Further Research and Developments: While the patent's claims demonstrate potential, they will likely require further validation through rigorous clinical trials. Moreover, ongoing studies exploring the application of ctDNA analysis in various cancer types will help determine the scope of the patent's impact on cancer diagnostics and treatment. Nonetheless, United States Patent 8852632 represents a significant milestone in the advancement of personalized medicine and offers promise for improved cancer patient outcomes.

Drugs Protected by US Patent 8,852,632

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Msd Sub Merck	ISENTRESS	raltegravir potassium	TABLET;ORAL	022145-001	Oct 12, 2007		RX	Yes	Yes	8,852,632		Y	Y		TREATMENT OF HIV INFECTION

International Family Members for US Patent 8,852,632

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2005311652
Brazil	PI0518781
Canada	2588445